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Abstract
Purpose
The CONSORT extension for patient reported outcomes (PROs) aims to improve reporting,
but guidance on the optimal integration with clinical data is lacking. This study examines in
detail the reporting of PROs and clinical data from randomized controlled trials (RCTs) in
gastro-intestinal cancer to inform design and reporting of combined PRO and clinical data
from trials to improve the ‘take home’message for clinicians to use in practice.
Materials and Methods
The case study was undertaken in gastro-intestinal cancer trials. Well-conducted RCTs
reporting PROs with validated instruments were identified and categorized into those com-
bining PRO and clinical data in a single paper, or those separating data into linked primary
and supplemental papers. Qualitative methods were developed to examine reporting of the
critical interpretation of the trial results (trial exegesis) in the papers in relation of the PRO
and clinical outcomes and applied to each publication category. Results were used to inform
recommendations for practice.
Results
From 1917 screened abstracts, 49 high quality RCTs were identified reported in 36 com-
bined and 15 linked primary and supplemental papers. In-depth analysis of manuscript text
identified three categories for understanding trial exegesis: where authors reported a
“detailed”, “general”, or absent PRO rationale and integrated interpretation of clinical and
PRO results. A total of 11 (30%) and 6 (16%) combined papers reported “detailed” PRO
rationale and integrated interpretation of results although only 2 (14%) and 1 (7%) primary
papers achieved the same standard respectively. Supplemental papers provide better
information with 11 (73%) and 3 (20%) achieving “detailed” rationale and integrated
PLOSONE | DOI:10.1371/journal.pone.0160998 August 29, 2016 1 / 20
a11111
OPEN ACCESS
Citation: McNair AGK, Macefield RC, Blencowe NS,
Brookes ST, Blazeby JM (2016) ‘Trial Exegesis’:
Methods for Synthesizing Clinical and Patient
Reported Outcome (PRO) Data in Trials to Inform
Clinical Practice. A Systematic Review. PLoS ONE
11(8): e0160998. doi:10.1371/journal.pone.0160998
Editor: Robert K Hills, Cardiff University, UNITED
KINGDOM
Received: April 18, 2016
Accepted: July 28, 2016
Published: August 29, 2016
Copyright: © 2016 McNair et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Support was provided by United Kingdom
Medical Research Council Collaboration and
innovation for Difficult and Complex randomised
controlled Trials In Invasive procedures Hub grant
code MR/K025643/1 director (to JMB). The funder
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
interpretation of results. Supplemental papers, however, were published a median of 20
months after the primary RCT data in lower impact factor journals (median 16.8 versus 5.2).
Conclusion
It is recommended that single papers, with detailed PRO rationale and integrated PRO and
clinical data are published to optimize trial exegesis. Further work to examine whether this
improves the use of PRO data to inform practice is needed.
Introduction
The updated Consolidated Standards of Reporting Trials (CONSORT) extension for patient
reported outcomes (PROs) aims to facilitate the use of PRO data in health policy and practice
through the transparent reporting of PROs in randomized controlled trials (RCTs)[1]. It
makes recommendations for reporting of PRO instrument validity, presentation and handling
of missing data and reporting of PRO sample size calculations, data analyses and results within
the main text and abstract. The statement endorses reporting the rationale/hypotheses for PRO
assessment and it highlights the need for integrated reporting of the PROs with the clinical
findings of the paper (extensions and elaborations 2a, 2b and P20/21 and 22). These latter rec-
ommendations are particularly essential for critical interpretation of the trial, so called exegesis
or a “take-home message”, for clinicians to understand and use results in clinical practice.
The CONSORT extension provides illustrations of how to report these issues. For example,
elaboration 2a and extension P2b state that authors should “briefly establish the rationale for
including PROs and why specific outcomes were selected”, and “report the rationale for the selec-
tion of specific patient-reported outcomes”. Furthermore, the guidelines state (in items P20/21
and elaboration 22) that “the clinical significance of PRO results is often not discussed in RCT
reports but should be interpreted in relation to other important clinical outcomes such as sur-
vival”. Whilst this is helpful, the level of detail required for reporting the PRO data is unclear and
this may have a detrimental impact on the overall clinically relevant trial conclusions.
This problem is further compounded by the way that PRO data are published. Some trials
publish results in a single paper combined with clinical findings, which may limit full explana-
tion of PRO results in the context of finite manuscript word limits. Publication of clinical and
PROs separately is therefore attractive, however, practicing oncologists may be less likely to
read the supplemental paper and thus not use PRO data in decision-making. The PRO CON-
SORT statement does not provide guidance for PRO reporting within these different scenarios.
Whether PRO data are published together with clinical outcomes or separately in two articles,
there is a need for optimal reporting of clinical and PROs so that they can be used in clinical
practice. The aim of this paper, therefore, is to explore current standards and make recommen-
dations for reporting a combined PRO and clinical ‘take home’message to use in reporting
RCTs in oncology.
Materials and Methods
This study was conducted in two parts. Part 1: systematic identification of well-designed and
conducted RCTs reporting PROs with validated instruments, categorisation of papers into
combined PRO and clinical reports or linked primary and supplemental reports, and assess-
ment of PRO reporting within each RCT (PRO CONSORT extension). Part 2: development of
novel methods to examine the ‘take home/trial exegesis’message of the RCT and application to
the papers identified in Part 1.
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Part 1(a) Identification of well-designed and conducted RCTs reporting
PROs with validated instruments
Systematic review methodology was used to identify RCTs at a low risk of bias reporting PROs
with validated instruments in radical treatments of gastro intestinal oncology. Full-text articles
were obtained. Gastro-intestinal oncology trials of radical treatment were chosen because the
research team were familiar with the clinical and PRO data in this area, and trials at a low risk
of bias are examples of best practice.
Electronic searches were performed in MEDLINE, Embase and Cochrane databases using
the OVID SP gateway and Cochrane library. Search terms for esophageal, gastric and colo-
rectal cancer were combined, as were terms for chemotherapy, radiotherapy, surgery or com-
bined treatment. Results were restricted with the application of terms for “randomized
clinical trials” and “patient reported outcomes”, and limited to articles published between
January 2000 and October 2012 (see full search in S1 Appendix). The search output was
imported into Reference Manager software and duplicate records removed. References for
relevant studies before the year 2000 were obtained from a previous systematic review [2].
Titles and abstracts were screened by two researchers (AGKM and RM). Serial publications
for the same trial (e.g. articles reporting short and long term PROs) were included. Excluded
were phase II studies, RCTs of endoscopic and non-biomedical interventions, or trials lim-
ited to palliative treatment, screening or premalignant conditions. Only English-language
publications were considered. Articles were assessed for risk of bias in the trials by three
researchers (AGKM, RM, NB) using the Cochrane tool [3]. Studies classified with potential
high or unascertainable risk of bias were excluded. Independent data extraction was con-
ducted by at least two reviewers (AGKM, NB, RM, JMB) using a pre-designed and piloted
form. Details of the trial were recorded including disease site, treatment intervention, pri-
mary and secondary outcomes, number of participants, and main trial results. The systematic
review PRISMA checklist is presented in S2 Appendix.
(b) Categorisation of papers into combined PRO and clinical reports or
linked primary and supplemental reports
Where included papers indicated the presence of previously published results from the same
trial, these additional papers were sought and included in the analysis. These linked papers are
hereafter considered in the order by which they were published, with those published first and
second defined as “primary” and “supplemental” respectively. Thus, trials were categorized
into those reporting PROs and clinical outcomes in a single, combined paper and those report-
ing results in linked primary and supplemental papers. The journal impact factor (Thomson
Reuters, 2012) and the date of publication for each paper were recorded. Descriptive statistics
compared journal impact factor for combined and linked primary and supplementary papers
and median times between publications were summarized.
(c) Assessment of PRO reporting using the new CONSORT extension
The PRO CONSORT extension was applied to all trials to establish standards of PRO report-
ing, with the exception of item P6a which was an inclusion criterion (use of a validated PRO
measure). Reporting of item 7a (PRO sample size) was recorded as present if a sample size cal-
culation was completed in trials with patient reported primary outcomes, or if it were not appli-
cable (for example, if there were no PROs as primary outcomes). Descriptive statistics are
presented to consider PRO CONSORT standards within trials reporting in a single, combined
publication or in linked primary and supplementary papers.
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Part 2 (a) Development of methods to present the ‘take home/trial
exegesis’message of PRO with clinical data in trials
Methods to report the ‘take home’messages of clinical and PROs in trials were developed
through an in-depth analysis of items 2a and P2b (rationale/hypotheses for PRO measure-
ment), and P20/21 and 22 (limitations and implications for clinical practice, and interpretation
of PROs in relation to clinical outcomes) to identify good practice and produce methods to
inform a PRO take home message from trials. All papers were read and re-read independently
by at least two (AM, RM and JMB) researchers to become immersed in the data and relevant
text was independently coded, copied verbatim into an electronic database and analysed for
consistency between researchers. Discrepancies in coding were discussed within the study team
(AM, RM and JMB). Methods for reporting trial ‘take home’message were developed and
applied iteratively to relevant text. Deviant examples were sought to challenge theories. Pri-
mary quotations are provided in accordance to methods of qualitative rigor. It was also noted
whether primary papers indicated the future publication of a supplemental PRO paper (defined
as “signposting”).
(b) Application of the novel methods to included trials
The methods described above were applied to the included trials and reported data examined
by whether trials were published in combined or linked primary and supplemental reports.
Results
Part 1(a) Identification of well-designed and conducted RCTs reporting
PROs with validated instruments
OVID (MEDLINE and Embase) and Cochrane database search yields were 1815 and 939 rec-
ords. After de-duplication, 1917 abstracts were screened, 1716 excluded, and 201 full text arti-
cles further assessed for eligibility, and these were supplemented with 13 studies from a
previous systematic review [2]. Sixty-seven articles met the inclusion criteria describing trials
at low risk of bias (Fig 1). The 66 included articles reported PROs from 49 RCTs, the majority
of which were chemotherapy interventions (22/49, 44.9%) in colorectal disease (36/49, 73.5%,
Table 1).
(b) Categorisation of papers into combined PRO and clinical reports or
linked primary and supplemental reports
Some 36 (71%) single papers reported combined PRO and clinical results and the remaining 30
were linked primary and supplemental papers. The median journal impact factor for both com-
bined and primary papers was the same (16.8), but supplemental PRO papers were reported in
journals with a lower median impact factor (5.2). The mean time between publication of linked
primary and supplementary papers was 20 months (range 5 to 51).
(c) Assessment of PRO reporting using the new CONSORT extension
Overall, the reporting of most papers did not meet the new PRO CONSORT standards (S1
Table). There were six (2 combined; 0 primary and 4 supplemental) papers reporting all PRO
CONSORT items (Table 2). Primary papers reported the fewest items (median 3, range 2 to 7),
typically lower than combined papers (median 6, range 2 to 12) and supplemental papers
(median 10, range 4 to 12). The least frequently reported items related to “results” (13a, 15, 16,
17a and 18), and were reported in less than one third of papers. The least frequently reported
Methods to Define Clinical 'Trial Exegesis'
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Fig 1. PRISMA diagram of stages of the systematic review.
doi:10.1371/journal.pone.0160998.g001
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items related to “results” (13a, 15, 16, 17a and 18), and were reported in less than one third of
papers.
Part 2 (a) Development of novel methods to examine the take home
message of PRO with clinical data in trials
The new method for understanding and improving combined reporting practice was developed
based upon the in-depth analyses, emergent data and iterative discussions with AM and JMB.
Sections of verbatim text were coded to items 2a and P2b were classified as providing a 1)
detailed rationale/hypothesis—when authors included a specific PRO domain and/or hypothe-
sized effect, 2) general rationale/hypothesis—when authors included non-specific rationale (i.e.
“to examine quality of life”) or 3) no rationale provided. Verbatim quotes of PRO rationales are
Table 1. Characteristics of included trials grouped by whether PRO and clinical data were presented
in combined PRO and clinical paper or separate primary and supplemental papers.
Combined clinical and PRO*
paper (n = 37)
Separate clinical and PRO
papers (n = 15)
N (%) N (%)
Trial type
• Chemotherapy 14 (37) (33)
• Radiotherapy 0 (14)
• Surgery 12 (32) (46)
•Other‡ 11 (30) 7 (46)
Disease site
• Esophagogastric 22.4) 0
• Colorectal 27 (72) 12 (80)
Sample size
• <100 8 (16) (7)
• 100–199 4 (10) (7)
• 200–499 13 (35) (33)
• 500–999 8 (21) (27)
• 1000–1999 3 (8) (27)
• 2000–3000 1 (3) 0
Primary outcome
• Survival 20 (54) (46)
• Response rate (8) 0
• Progression/ recurrence 6 (16) (13)
• PRO (16) 0
• Hospital stay (5) 0
• 30 day post-op morbidity 0 (7)
• Diarrhea (3) 0
• Pulmonary infection (3) 0
• Unclear 2 (5) 0
Journal impact factor Median (range) Median (range)
• Primary paper 16.8 (2.8 to 50) (5.1 to 50)
• Supplemental paper 5.2 (2.1 to 30)
Time between primary and
supplemental paper (months)
n/a 20 (5 to 51)
‡other biochemical modulators e.g.monoclonal antibody, radioactive yttrium
* PRO: Patient reported outcome
doi:10.1371/journal.pone.0160998.t001
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presented in Tables 3 and 4. An example of a detailed rationale included: “. . .we hypothesized a pri-
ori that [intervention] would result in a decrease in the magnitude and rate of decline in HRQL,
particularly in physical function and overall well-being”[4], and an illustration of a general rationale
included “. . .to compare. . .quality of life. . .between [intervention] and [control]”[5].
Likewise, sections of text coded to the items P20/21 and 22 were developed as 1) detailed
interpretations—where authors discussed the hypothesized effect of a specific PRO in relation
to the hypothesized effect of a clinical outcome, 2) general interpretations–when authors
include non-specific interpretation of PROs in relation to clinical outcomes, or 3) no integrated
PRO and clinical interpretation of results in the paper. An example of detailed interpretation of
findings includes “. . . [Intervention] resulted in significantly improved TTP [time to progres-
sion] (primary end point), OS [overall survival], and overall response rate (secondary end
points), with global health status (quality of life). . . preserved for a longer time.”[6]
Part 2, b) Application of the methods to included trials
Of the 36 trials reporting combined papers, there were 11 (30%) papers that provided a PRO
rationale/hypothesis, 10 (30%) providing general information and 15 (40%) not providing a
Table 2. Analyses of reporting PROCONSORT extension criteria, grouped by combined PRO and clinical papers, or separate primary and supple-
mental papers.
CONSORT PRO item Combined clinical and PRO paper (n = 36) Separate clinical and PRO
papers (n = 15 pairs)
Total(n = 66)
1° 2°
N (%) N (%) N (%) N (%)
P1b The PRO should be identiﬁed in the abstract as a
primary or secondary outcome.
28 (78) 4 (27) 15 (100) 47 (71)
2a/P2b* The relevant background and rationale for why
PROs were assessed in the RCT should be brieﬂy
described/ The PROs hypothesis should be stated
and relevant domains identiﬁed, if applicable.
22 (61) 5 (33) 15 (100) 42 (64)
P6a** Evidence of PRO instrument validity and reliability
should be provided or cited, if available.
36 (100) 15 (100) 15 (100) 66 (100)
7a† How PRO sample size was determined 33 (92) 15 (100) 15 (100) 63 (95)
P12a Statistical approaches for dealing with missing data
are explicitly stated
9 (25) 1 (7) 10 (66) 20 (30)
13a The number of PRO outcome data at baseline and at
subsequent time points should be made transparent
6 (17) 1 (7) 9 (60) 16 (24)
15 A table showing baseline demographic and clinical
characteristics for each group including PRO data
7 (19) 0 10 (67) 17 (26)
16 For each group, number of participants
(denominator) included in each analysis and whether
the analysis was by original assigned groups
8 (22) 0 8 (53) 16 (24)
17a For multidimensional PROs, results from each
domain and time point speciﬁed for analysis.
9 (25) 0 10 (67) 19 (29)
18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses,
distinguishing prespeciﬁed from exploratory
including PRO analyses, where relevant
10 (28) 3 (20) 7 (46) 20 (30)
P20/21‡ PRO–speciﬁc limitations and implications for
generalizability and clinical practice
29 (81) 3 (20) 14 (93) 46 (70)
22‡ PRO data should be interpreted in relation to clinical
outcomes including survival data, where relevant
29 (81) 3 (20) 14 (93) 46 (70)
* For more detailed analysis of items 2a/P2b see Table 3
** Study inclusion criteria
†Only applicable to trials with PROs as primary outcome (n = 6, all combined papers).
‡ For more detailed analysis of items P20/21/22 see Table 3
doi:10.1371/journal.pone.0160998.t002
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Table 3. Reported PRO rationale (items 2a and P2b) and authors’ interpretation of PRO in relation to clinical findings (items P20/21 and 22) in pri-
mary reports of trials with separate primary and supplemental papers. Extracted text was abridged where appropriate, as indicated by a series of peri-
ods (. . .), but otherwise presented verbatim.
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings: Level of
detail†
Ajani [6] [7] 1° “To investigate whether adding [intervention] to
[control] could improve patient outcomes (time-to-
progression [TTP], overall survival [OS}, quality of
life. . .” “Time to 5% deﬁnitive deterioration in global
health status assed by QLQ-C30 was the primary
quality of life parameter. “
Detailed “. . . [Intervention] resulted in signiﬁcantly improved TTP
(primary end point), OS, and overall response rate
(secondary end points), with global health status
(quality of life). . . preserved for a longer time.”
Detailed
2° “. . .to investigate whether the better efﬁcacy with
[intervention] was counterbalanced by. . .the
impact. . .on patient QOL” “The primary endpoint of
the QOL assessment was. . .global health status”
Detailed “.. signiﬁcantly better preservation of QOL for patients
treated with [intervention].. as a result of a signiﬁcantly
higher level of efﬁcacy. . . . despite a higher incidence
of some toxicities. . .”
General
Au[4] [8] 1° “. . .no trials have demonstrated an effect of
[intervention] on. . . .quality of life. . .” “The secondary
end points were. . .quality of life, assessed by mean
changes in scores of physical function and global
health status..”
Detailed “[Intervention] improves overall survival and
progression-free survival and preserves quality of life
measures. . .”
General
2° “. . .. we hypothesized a priori that [intervention]
would result in a decrease in the magnitude and rate
of decline in HRQL, particularly in physical function
and overall well-being.”
Detailed “Patients who received [intervention] experienced
signiﬁcantly less HRQL deterioration and a longer time
before clinically signiﬁcant deterioration occurred.
These results are important, because. . .although
[intervention]. . . results in improved OS, PFS, RR, and
DCR. . .the magnitude of these beneﬁts. . .was not
large.” “. . .[intervention] offers clinically important
survival and HRQL beneﬁts. . .”
General
de Boer [9]
[10]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .to compare the quality of life of patients. . .who
underwent [intervention] with patients.. who
underwent [control]”
General “..comparing. . .quality of life..is of great interest
because a choice between the..two treatment options
proves to be difﬁcult..based on overall survival.
However. . .no lasting differences in the quality of life of
patients. . .were found.”
General
Braga[11]
[12]
1° “To clarify the value of [intervention]. . .quality of
life. . .should be considered”
General “[intervention] resulted in earlier postoperative
recovery, better cosmesis and improved quality of
life. . .compared to [control].”
General
2° “The primary endpoint was to compare the impact of
[intervention] and [control] on 30-day postoperative
morbidity.” “Recovery of social and physical activity
was evaluated. . .by a speciﬁcd adaptation of the SF-
36. . .”
Detailed “. . .the [intervention] resulted in a reduction of both the
overall morbidity rate and the length of hospital stay,
and in a faster recovery of physical and social activity.”
Detailed
Chau [13] [14] 1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .to assess QOL. . . .in patients receiving
[intervention]”
General “[Intervention] was associated with signiﬁcantly better
quality of life. . . Due to the shorter treatment duration,
[intervention] had a faster time of QOL recovery. Quality
adjusted survival was also in favour of the
[intervention]. . .
General
Hallböök [15]
[16]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “We hypothesized that such clear differences in
clinical bowel function [with the intervention] would
also be reﬂected in the score of a general quality of
life instrument. . .. . .”
Detailed “The observed difference in clinical bowel function was
not. . . reﬂected in an improved QOL score. . .”
General
Janson [17]
[18]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .with the hypothesis that [intervention] results in
an improved HRQL when compared with [control]”
Detailed “HRQL was better..after [intervention]. At present,
several studies indicate that the oncologic results are at
least equal after [intervention].”
General
(Continued)
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Table 3. (Continued)
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings: Level of
detail†
Kabbinavar
[19] [20]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “The primary HRQoL endpoint was the time to
deterioration in HRQoL measured by the Colorectal
Cancer Subscale score”
Detailed “this prospective HRQoL analysis supports the clinical
beneﬁt of [intervention] in improving time to disease
progression and prolonging overall survival, without
compromising patients’ HRQoL”.
General
King [5] [21] 1° “The aim of this study was to compare. . . quality of
life. . .in a prospective group of patients undergoing
[intervention]”
General “Patients undergoing [intervention] stay in hospital half
as long. . .with no. . .deterioration in quality of life. . .”
“. . .clinical improvements resulting from [intervention]
did not cause signiﬁcant deterioration in quality of
life. . .”
General
2° “. . .to compare recovery after [intervention] and
[control]. . .using. . .self-report and observer data.”
General “The earlier discharge in the [intervention] group did not
result in any deterioration in quality of life outcomes
compared with those in the [control] group” “Despite
perioperative optimization of [control], short-term
outcomes were better following [intervention]. There
was no deterioration in quality of life or increased cost
associated with the [intervention].”
General
Kopec [22]
[23]
1° “A secondary aim was to compare quality of life. . .” General No integration of PRO and clinical data Absent
2° “We hypothesized that the [intervention] would be
associated with higher HRQL and that it would be
perceived as more convenient.” . . .. “The primary
end point for this study was the FACT-C total score.”
Detailed “The efﬁcacy of the two regimens is similar, as
demonstrated.. by the survival and disease-free
survival analyses. . . This underscores the importance
of patient-reported outcomes..” “Both regimens . . . do
not differ in their impact on HRQL.”
General
Marijnen [24]
[25]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .we studies the effects of [intervention] on the
HRQL and sexual functioning. . .”
Detailed “The results of this study enable physicians and
patients to weigh the beneﬁcial effect of [intervention]
on local recurrence against the price to be paid in terms
of HRQL and sexual functioning.”
Detailed
Siena [26]
[27]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .exploratory analyses were conducted that
assessed the association between [trial outcome
variables] and HRQoL”
General “. . . lack of disease progression was associated with . . .
higher HRQoL for [intervention] patients only. . .Lack of
disease progression was associated with better
symptom control, HRQoL, and OS.
General
Stephens [28]
[29]
1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “. . .the advantages of [intervention] to all patients
needs to be balanced against any negative impact
on patients’ quality of life”. “. . .the primary quality-of-
life aims as “What is the longer-term (2-year) effect of
the treatments on (1) sexual function and (2) bowel
function?” Secondary outcome measures were
“What is the effect of treatment on physical function
and general health?” To address these questions,
the sexual dysfunction and bowel function scales
from the QLQ-CR38 and the physical function and
general health scales from the MOS SF-36 were
used.”
Detailed “Therefore our results, together with those of the Dutch
trial, provide convincing data on the impact of surgery
and PRE on sexual and bowel function.” “The
information presented in this article should allow
clinicians to discuss with patients an estimate of the
beneﬁt of PRE in terms of reduction in LR risk balanced
against the detrimental toxicity that is attributable to
PRE.”
Detailed
Weeks [30]
[31]
1° No PRO rationale Absent “The detailed quality of life component of this trial
suggests that greater beneﬁts in terms of the quality of
life and recovery may be possible if fewer procedures
are converted.”
General
(Continued)
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PRO rationale (Table 5). The interpretation of PRO data in the context of clinical outcomes
were detailed in six (16%), general in 24 (65%) and absent in 7 (17%) papers (Items P20/21 and
22, Table 3). There were seven papers that described both detailed PRO rationale/hypotheses
and detailed interpretations of PROs in relation to clinical outcomes [5, 6, 13, 26, 30, 68, 70].
Where PRO and clinical results were published separately (n = 15), most primary papers
did not provide any PRO rationale (n = 10, 66%) or text interpreting PROs in relation to clini-
cal findings (n = 10, 66%). One primary paper provided detailed descriptions of both these
issues. In comparison, all supplemental papers described PRO rationales and most (14, 93%)
contained detailed interpretation of PROs in relation to clinical findings, although only two
had detailed descriptions of both of these. Of the 15 primary papers, 66% signposted the pres-
ence of the supplemental PRO report.
Conclusions
Reporting PRO rationale linked to clinical hypotheses, and clear reporting of PRO results inter-
preted appropriately in the context of the clinical outcomes are critical to ensure that oncolo-
gists gather a “take-home”message to communicate to patients which encompasses clinical
and PROs. This review explored this issue in detail. Patient reported outcome reporting stan-
dards were at lowest levels in primary clinical papers (where clinical trial data was reported sep-
arately to the supplementary PROs). Whilst supplemental papers provided more detail there
was a 5 to 51 month delay in publication in less well cited journals, thus diminishing their
impact. Most (71%) trials did report combined results, demonstrating that it is possible to do
so. New methods to examine reporting of trial “take home”messages recommend that detailed
information about domain specific PRO rational and interpretation with clinical data are sup-
plied within a main trial paper to arm clinicians with relevant outcomes to use in decision-
making. Authors need to be allowed space to report these details alongside clinical outcomes to
inform the take home message from papers to help clinicians in practice. Where this is not
appropriate for scientific reasons, for example, if primary outcome data are available before
secondary PROs, then this could be explicitly stated.
Table 3. (Continued)
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings: Level of
detail†
2° “The trial was also designed to test the hypothesis
that [intervention] is associated with superior QOL
outcomes” “the study protocol speciﬁed. . .the
variability in pain distress item and the global ratings
scale”
Detailed “[Intervention].. results in statistically signiﬁcant but
clinically modest decreases in the duration of
postoperative in-hospital analgesia and in length of
stay. . . However, these differences do not translate into
statistically signiﬁcant improvements in symptoms or
QOL. . .”
General
Wu[32] [33] 1° No PRO rationale Absent No integration of PRO and clinical data Absent
2° “We hypothesised that patients receiving [the
intervention] would have more symptoms and
greater fatigue than patients receiving [the control],
with treatment arms difference most prominent at the
6-month assessment, and probably continuing up to
1 year after random assignment.”
Detailed “Although the morbidity rate was higher in [intervention]
patients than in [control] patients, our analysis indicates
that [intervention] did not adversely inﬂuence QOL”
General
* Detailed rationale/hypothesis: specifying a PRO domain or hypothesized effect; general rationale/hypothesis: any other description; absent: no rationale.
See methods for more details
† Interpretation was considered “detailed” where authors discussed the direction of change (e.g. increased/decreased/no change) of a speciﬁc PRO domain
(e.g. physical function) in relation to the direction of change of a speciﬁc clinical outcome (e.g. survival). All other discussions, where present, were
considered “partial” interpretations. Where no appropriate text was identiﬁed, interpretation was considered “absent”. See methods for more details
doi:10.1371/journal.pone.0160998.t003
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Table 4. Reported PRO rationale (items 2a and P2b) and authors’ interpretation of PRO in relation to clinical findings (items P20/21 and 22) in
reports of trials with combined clinical and PRO papers. Extracted text was abridged where appropriate, as indicated by a series of periods (. . .), but oth-
erwise presented verbatim.
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings Level of
detail†
Biere [34] “We compared [intervention] with [control]. . . to assess
the rate of pulmonary infection and quality of life
associated with [intervention]”
General “In this trial, [intervention] resulted in a lower incidence of
pulmonary infections 2 weeks after surgery and during
stay in hospital, a shorter hospital stay, and better short-
term quality of life than did [control], with no compromise
in the quality of the resected specimen.” “Additionally,
[intervention] preserved quality of life better than
[control] did. After 6 weeks, the SF 36 questionnaire and
global health experience in the EORTC C30 module
were better for patients in the [intervention] group than
for those in the [control] group. In the oesophageal-
speciﬁc OES 18 questionnaire, pain and talking were
adversely affected in patients in the [control] group as
compared with those in the [intervention] group.”
Detailed
Bramhall [35] No PRO rationale Absent No integration of PRO and clinical data Absent
Carmichael
[36]
No PRO rationale Absent “The safety advantages of [intervention] surprisingly did
not lead to demonstrable improvement in quality of life.”
General
Cunningham
[37]
No PRO rationale Absent No integration of PRO and clinical data Absent
de Gramont
[38]
“. . .to compare the two treatments in terms of. . .QoL” General “The [intervention] seems beneﬁcial. . ., demonstrating a
prolonged progression free survival with acceptable
tolerability and maintenance of QoL.” “Median QoL
scores were similar for the two arms. . ., despite the
increased incidence of [treatment]-related side effects
. . .”
General
Doeksen [39] “The objective. . .was to compare functional and
surgical results of [intervention] with [control] and their
impact on quality of life.” “The primary end-point was
the function. . . assessed at 12 months by the validated
COlo-Rectal Functional Outcome (COREFO)
questionnaire’s summary score.”
Detailed “. . .a better functional outcome was found in patients
with [intervention] than [control]. These functional
differences did not inﬂuence health-related and overall
quality of life.”
General
Douillard [40] “The QLQ-C30 questionnaire was analysed with the
global health status/QoL scale (QL) as the primary
endpoint. . .”
Detailed “[Intervention] was well-tolerated and increased
response rate, time to progression, and survival, with a
later deterioration in quality of life.” †
General
Douillard [41] No PRO rationale Absent “It was surprising that there was no observed difference
between the treatment arms in quality of life, despite the
clear reduction in toxicity with [intervention].”
General
Fein [42] “. . .to identify optimal [treatment] in terms of quality of
life”
General “There were no differences in operative time,
postoperative complications, and mortality.., there were
no beneﬁts of [intervention] in terms of quality of life,
independent of the resection status. In the third, fourth,
and ﬁfth year after surgery quality of life was signiﬁcantly
improved for patients with [intervention].
General
Fields [43] No PRO rationale Absent No integration of PRO and clinical data Absent
Fuchs [44] “. . .to compare. . .effect on patient quality of life of
these two [treatments]”
General “This. . . trial provides comparative data on the efﬁcacy,
tolerability, and effect on patient quality of life between
the [treatments].”
General
Furst [45] “. . .we tested [intervention] with [control] for. . . .quality
of life. . .”
General No integration of PRO and clinical data Absent
Gray [46] “. . .to assess whether [intervention] could. . . .change
quality of life”
General “No decrease in quality of life was observed which is in
accord with the lack of serious toxicity and treatment-
related complications.” “[intervention] increases
treatment effectiveness when measured by tumor
response and time to disease progression and suggests
an increase in survival for patients surviving more than
15 months. [Intervention] does not compromise quality
of life or add signiﬁcant toxicity.”
General
(Continued)
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Table 4. (Continued)
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings Level of
detail†
Guillou [47] No PRO rationale Absent “no differences were recorded between [control] and
[intervention]. . . with respect to tumour and nodal status,
short term endpoints, and quality of life.”
General
Hoksch [48] “. . .to evaluate the quality of life during the ﬁrst
postoperative year comparing [intervention] and
[control]”
General “In this study of global health status and quality of life,
patients operated on with [control procedure] did not
reach their preoperative values compared to the patients
with the [intervention]. . .” “The clinical advantage
manifested 6 months after operation. . . For that reason
only patients with a good long-term prognosis might
beneﬁt from [intervention].
Detailed
Jayne [49] No PRO rationale Absent “[Intervention]. . . . is as effective as [control] in terms of
oncological outcomes and preservation of QoL”
General
Kang [50] No PRO rationale Absent “. . .[intervention] is feasible and does not increase short-
term oncological risks, which are predicted by CRM
positivity and macroscopic quality of TME specimens. . .
The results of this trial also suggest that [intervention]
results in a better quality of life for up to 3 months. . .”
General
Kataria [51] “To compare the quality of life (QOL) in patients
undergoing [intervention] with [control]. . .” “The
objective of this study is to assess the QOL following
[intervention]. . .”
General No integration of PRO and clinical data Absent
Kemeny [52] “We hypothesized that patients in the [intervention] arm
would have better physical and social functioning,
fewer role limitations due to their emotional health, and
better health perceptions than patients in the [control]
arm.”
Detailed “[Intervention] prolonged the median survival. . . was
associated with a greater likelihood of objective tumor
responses. . ., enhanced time to hepatic progression. . .,
and improved physical functioning (QoL
measurements).”
Detailed
Kohne [53] No PRO rationale Absent No integration of PRO and clinical data Absent
Lal [54] “No studies have evaluated whether [intervention] is
superior. . .in terms of. . .quality of life”
Detailed “There were no improvements in failure-free survival
from continuing [intervention]. . . . However,.. there was
no deterioration in QoL. . .”
General
Maughan [55] “Several speciﬁc quality-of-life endpoints were
predeﬁned in the protocol: palliation of key symptoms,
toxic effects, psychological effect, functional status,
social functioning, and overall quality of life”
Detailed “[A] and [B] regimens were similar in terms of survival,
quality of life, and response rates. [C] showed similar
response rates and overall survival to the [A] regimen
and was easier to administer, but resulted in greater
toxicity and inferior quality of life.”‡ “Since there was
similar overall survival, quality of life became an
important outcome measure.”
General
Punt [56] “The primary objective. . .was to examine the treatment
effect on the mean global health status score. . .”
Detailed No integration of PRO and clinical data Absent
Punt [57] “The primary objective. . .was to examine the treatment
effect on the mean global health status score. . .”
Detailed “[Intervention]. . .results in a small but signiﬁcant
improvement in progression free survival without adding
toxicity or worsening QoL. . . .” †
General
Rao [58] No PRO rationale Absent “Although there was a trend in favor of [intervention] for
progression free survival, and more patients had stable
disease, this did not translate in an improved QOL or
survival advantage.”
General
Ross [59] “. . .we report results. . .comparing [intervention] with
[control] using. . .QOL. . .as the study’s end points”
General “The equivalent efﬁcacy of [intervention] was
demonstrated, but QOL was superior with [control].”
General
Sailer [60] “Randomised trials. . .have shown functional
superiority of [intervention]. . .it was hypothesized that
signiﬁcant differences in bowel function should also be
reﬂected in quality of life” “Sample size analysis was
based on. . .global health status. . .”
Detailed “. . .patients undergoing [intervention] may not only
expect better functional results but also an improved
quality of life. . .”
General
Saini [61] “. . .to assess QOL of patients undergoing [treatment]” General “this study has demonstrated that the [intervention] is
associated with less acute toxicity and less impairment
of QOL than [control]. Furthermore, this has been
achieved without any obvious adverse effect on
outcome”
General
(Continued)
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Other systematic reviews have shown that PRO reporting standards are poor [71–77] which
contributed to the need for the development of the PRO CONSORT extension. Similarly, other
papers have recommended clear PRO hypotheses and integration with clinical findings, how-
ever, there is no empirical data presented on how to best achieve this [78]. Reviews also have
examined how PROs in RCTs influence decision-making and confirm that PRO information is
not used in practice [77, 79, 80]. Previous work, however, has not provided solutions to these
problems or considered the conceptual reasons why PRO data are not used in practice. Theo-
retically, failure of PRO data to have an impact on clinical practice may stem from problems
that start with the trial design and conduct, compounded by poor reporting and separate PRO
and clinical publications. Further research is now needed to investigate whether improved
reporting will have the desired effect of informing patient-centred care, clinical decision
Table 4. (Continued)
Author
[citation]
PRO rationale Level of
detail*
Interpretation of PRO in relation to clinical ﬁndings Level of
detail†
Saltz [62] No PRO rationale Absent “the [intervention] was associated with higher rates of
tumor regression, progression-free survival, and overall
survival without compromising the quality of life.”
General
Sobrero [63] No PRO rationale Absent “.. Progression free survival was signiﬁcantly longer in
experimental. . ., while the overall survival was similar in
both arms. . .; quality of life was similar as well.” †
General
Sobrero [64] No PRO rationale Absent “.. [intervention] reduced the risk of progression.., and
improved median progression free survival. . ., and
response rate.. The QOL assessments also support this
beneﬁt. Global health status as well as physical,
emotional, and cognitive functioning were signiﬁcantly
better with [intervention].”
Detailed
Tebbutt [65] No PRO rationale Absent “the addition of [intervention]. . .has no effect on
response rates compared with [control]. In addition,
there was no signiﬁcant effect on overall survival or
quality of life,. . .”
General
Tol [66] No PRO rationale Absent “the [intervention] resulted in a signiﬁcant decrease in
progression free survival and a poorer quality of life”
General
Van Hooft [67] “We aimed to establish whether [intervention] has
better health outcomes than does [control]” “The
primary outcome was mean global health status. . .
assessed with the QL2 subscale of the European
Organisation for Research and Treatment of Cancer
quality of life questionnaire.” “This measure was
chosen because the outcome of the treatments, such
as need for a stoma, incisional hernia, lengthy intensive
care, and hospital stay, might affect patients’ quality of
life”
Detailed “. . .[intervention] or [control] did not have any distinct
beneﬁts for global health status, mortality, morbidity,
other quality of life dimensions, and stoma rates.”
Detailed
Vlug [68] “. . .combining the [intervention] will result in the fastest
postoperative recovery.”
Detailed “Treatment groups had similar morbidity, reoperation
and readmission rates, equal in-hospital mortality,
comparable levels of quality of life. . .”
General
Zachariah [69] . . . .”if [intervention] was efﬁcacious in reducing
treatment-induced diarrhea, better QoL and bowel
scores were expected for the [intervention] for all
instruments.”
Detailed “We found that [intervention] did not show a statistically
signiﬁcant reduction in the incidence or severity of
diarrhea or change in patient-reported bowel function. . .”
Detailed
* Detailed rationale/hypothesis: specifying a PRO domain or hypothesized effect; general rationale/hypothesis: any other description; absent: no rationale.
See methods for more details
† Interpretation was considered “detailed” where authors discussed the direction of change (e.g. increased/decreased/no change) of a speciﬁc PRO domain
(e.g. physical function) in relation to the direction of change of a speciﬁc clinical outcome (e.g. survival). All other discussions, where present, were
considered “partial” interpretations. Where no appropriate text was identiﬁed, interpretation was considered “absent”. See methods for more details
doi:10.1371/journal.pone.0160998.t004
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making and health policy decisions. For example, work could include a study directly exploring
oncologists’ views of trial reports following the introduction of new reporting guidelines would
be informative. Additionally in-depth research of clinical decision-making in multi-disciplin-
ary teams or of oncology consultations may be undertaken to examine how PRO data are used.
Research needs to be targeted into each of these areas in order to understand how improve-
ments, such as the recently published SPIRIT statement [81] for improving RCT protocols or
the CONSORT PRO extension, impact clinical practice. What is clear is that cancer patients
want information about PROs and indeed rate such data of similar importance to survival
information [82–84]. It is therefore critical that oncologists communicate PRO data in the con-
text of a shared doctor-patient consultation and methods to do so are being established [85–
87]. This may have occurred because authors split trial results and deliberately left the PRO
methodology and findings to the supplemental report.
This review included a systematic search for studies using PRISMA guidelines [88] and
transparent methodology for an in-depth analyses if the textual data, but there were some limi-
tations. Trials of radical treatments of gastrointestinal cancers were selected for analyses
because the authors were familiar with the PRO and clinical data in this field. It is conceivable
that including trials in other diseases or in the palliative setting may have identified different
reporting standards. For example, in the palliative setting, authors may make greater reference
to PROs and their integration with clinical outcomes because the main focus of treatment is
not to cure disease. Further work is needed to examine this area in detail. In addition, studies
with high or unascertainable risk of bias were excluded because lower standards of reporting
are associated with bias and likely poor PRO reporting [89], and it is possible that important
data were missed. This is considered to be unlikely however, because even the included “high-
quality” trials demonstrated significant reporting weaknesses and inclusion of poor quality tri-
als would probably not yield exemplar practice.
Table 5. Novel methods for assessing CONSORT PRO extension items 2a/P2b and P20/21/22,
grouped by combined PRO and clinical papers, or linked primary and supplemental papers (n = 67).
CONSORT PRO item Combined clinical and PRO paper (n = 36) Linked clinical
and PRO
papers (n = 15
pairs)
1° 2°
N (%) N (%) N (%)
Rationale/hypothesis (2a/P2b)*
• Detailed 11 (31) 2 (14) 73)
•General 10 (28) 3 (20) (27)
• Absent 15 (41) 10 (66) 0
Interpretation of ﬁndings (P20/21/22)†
• Detailed 6 (17) 1 (7) (20)
•General 2 (64) 4 (27) 80)
• Absent 7 (19) 10 (66) 0
* Detailed rationale/hypothesis: specifying a PRO domain or hypothesized effect; general rationale/
hypothesis: any other description; absent: no rationale. See methods for more details
† Interpretation was considered “detailed” where authors discussed the direction of change (e.g. increased/
decreased/no change) of a speciﬁc PRO domain (e.g. physical function) in relation to the direction of change
of a speciﬁc clinical outcome (e.g. survival). All other discussions, where present, were considered “partial”
interpretations. Where no appropriate text was identiﬁed, interpretation was considered “absent”. See
methods for more details
doi:10.1371/journal.pone.0160998.t005
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In summary, this review presents and evidence based way of implementing the new CON-
SORT PRO extension items 2a, P2b, P20/21 and 22 based on current literature. It is recom-
mended that RCTs report domain-specific PRO rationale with anticipated treatment effects,
and integrate these findings with specific clinical outcomes in a single combined report. It is
acknowledged that trials are structured around their primary (often clinical) endpoints, and it
is appropriate to prioritise these data at the expense of other outcomes. It seems unnecessary,
however, to relegate evaluation of patient experience to reports that may be less likely to influ-
ence practice. The adoption of better standards for PRO reporting could facilitate the use of
PRO data by oncologists and patients for informed decision making.
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